Pharma Business Week articles from November 2004

Pharma Business Week archives from November 2004

Minute doses of JNJ-17029259 enhance the utility of standard chemotherapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Minute doses of JNJ-17029259 enhance the utility of standard chemotherapy. "Inhibition of angiogenesis may have wide use in the treatment of cancer; however, this approach alone will not cause tumor...

FDA grants priority review to Pegasys with Copegus for HCV in HIV patients.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has granted 6-month priority review status to the supplemental new biologics license application (sBLA) for Roche's combination therapy of Pegasys...

Investigational therapy for bone loss increased bone mineral density.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) announced that at all doses studied, twice yearly injections of AMG 162, the company's investigational therapy for bone loss, significantly increased bone mineral density (BMD) at...

Chronic opiate use may raise vulnerability to stress.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Chronic use of opiate drugs may alter brain neurons to make animal brains more sensitive to stress, according to a new study. If the research proves applicable to humans, the findings may help...

Agilect provides significant symptom benefit as monotherapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Agilect (rasagiline mesylate) taken once-daily significantly improved symptoms of Parkinson disease (PD) both as initial monotherapy in patients with early PD and as adjunct treatment to levodopa in...

Biotechcompany scientist presented with award from Alzheimer Association.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Prana Biotechnology Limited (NASDAQ:PRAN)(NASDAQ:ASX:)(NASDAQ:PBT) announced that Dr. Ashley Ian Bush, cofounding scientist and senior scientific consultant to Prana Biotechnology, was named a 2004...

Forecast: Considerable research to be devoted to pathomechanism of Alzheimer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Management of Alzheimer disease remains a challenge, with nearly 8 million sufferers from this condition in the 7 major world markets and anticipated increases in the future. Considerable research...

Partnership between government, industry will streamline clinical trials.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The U.S. National Institute on Aging (NIA) is launching a landmark study to find neuroimaging and other methods for monitoring the progression of Alzheimer disease (AD) aimed at significantly reducing...

Pharma company announces progress with Alzheimer strategy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has made steady progress pursuing a multipronged strategy against Alzheimer disease (AD) that targets the prevention, diagnosis and treatment of AD,...

Pharma company's long-term study of Celebrex expected to continue.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Pfizer Inc. said that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to...

CytRx adds three drug candidates with acquisition of Biorex assets.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- CytRx Corp. (CYTR) has acquired all the clinical and pharmaceutical assets and related intellectual property of Hungary-based Biorex Research & Development, RT, (Biorex), a privately held biotechnology...

Phase I trial of Hematide initiated.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Affymax, Inc., announced that it has initiated a placebo controlled, phase I dose-finding clinical trial with its lead product candidate, Hematide, a peptide-based erythropoiesis stimulating agent (ESA)...

JCAHO Sentinel Event Alert issued targeted at preventing anesthesia awareness.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Aspect Medical Systems (ASPM) announced that the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has issued a new Sentinel Event Alert (issue no. 32) aimed at preventing and...

Biotech company working to address problem of antibiotic resistance.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- New biotechnology company, RiboNovix, Inc., is addressing the worsening problem of antibiotic-resistant bacteria by developing new anti-infectives that are less susceptible to drug resistance. Over...

Antisense inhibitors of TRADD could modulate TNF-related pathologies.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Antisense inhibitors of TRADD could modulate TNF-related pathologies. "Tumor necrosis factor (TNF) receptor 1-associated death domain protein (TRADD) is an adaptor protein known to be involved in...

Pharmaceutical company offers its alternative to recalled arthritis medication.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- With the recent recall of the arthritis medication rofecoxib, Boehringer Ingelheim announced that it is supporting patients while they look for new alternatives. The company offered up its own...

Suite of asthma control and asthma impact surveys launched.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- QualityMetric Incorporated announced launch of a full suite of asthma control and asthma impact surveys for adults and children that measure health-related quality of life (HRQoL) from the patient...

Results presented on antibody-based treatment of atherosclerosis.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A new report describes the research performed by a research team lead by professor Jan Nilsson at the University Hospital MAS in Malmo in collaboration with BioInvent International AB (BINV) in Lund....

Biotech firm lauds Nobel winner, announces olfactory-based government contract.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Joseph K. Pagano, chairman of the board of Sentigen Holding Corp. (SGHL), a biotechnology company, extended congratulations to Dr. Richard Axel, Sentigen's long term good friend and consultant, on being...

Pharma company completes phase 1 clinical trial for complicated skin infections.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Peninsula Pharmaceuticals, Inc., announced that is has completed a phase 1 clinical trial for PPI-0903, one of its product candidates. Peninsula is investigating PPI-0903 as a potential treatment...

Avodart offers improvements in quality of life for men with prostate problems.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Men who suffer from benign prostatic hyperplasia (BPH) experience long-term benefits with the new treatment Avodart, according to a new study. For the first time, the study looked at the effects of...

Statistically significant positive phase II data reported on Cetrorelix.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- AEterna Zentaris, Inc., (AEZ; AEZS) announced statistically significant positive results from a randomized, double-blind, placebo-controlled phase II trial designed to evaluate different dosage regimens...

Peptidomics offers sensitive search for biomarkers.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The German biotech company BioVisioN opens up new possibilities for peptide biomarker research. Improvements of their proprietary Clinical Peptidomics technologies were presented at this year's...

Microarrays donated to Vanderbilt University.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Agilent Technologies, Inc., (A) and Vanderbilt University Medical Center (VUMC) announced that Agilent has donated cDNA microarray kits valued at $66,000 to the medical center. VUMC expects to use...

BioProcess International Conference & Exhibition unites 1,000 attendees.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The first-ever BioProcess International Conference & Exhibition in October united more than 1,000 attendees from worldwide biotech and pharmaceutical companies at the Boston Convention & Exhibition...

More than 1 million Bioanalyzer chips sold.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Agilent Technologies, Inc., (A) announced that it has sold more than one million LabChip chips - small, analytical devices used with the Agilent 2100 bioanalyzer to perform fast, automated analysis of...

Brain metastases patients' radiographic response at 3 months predicts survival.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- For brain metastases patients undergoing whole brain radiation therapy (WBRT), radiographic response in the brain at 3 months is a statistically significant predictor of prolonged survival, according to...

New findings from EFAPROXYN brain metastases trial releases.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (NASDAQ:ALTH) announced the presentation of new findings from its phase 3 clinical trial of the investigational radiation sensitizer EFAPROXYN (efaproxiral) in patients with...

Positive cancer data on ECO-4601 presented at symposium.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Ecopia BioSciences, Inc., (EIA) presented data on ECO-4601 in a poster entitled "A new antitumor compound, ECO-4601: Preclinical evaluation and in vivo efficacy in glioma" at the European Organization...

Medical device company announces kit for accelerated partial breast irradiation.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Nucletron B.V. announced the release of OncoSystem Breast, a complete turnkey kit for accelerated partial breast irradiation (APBI). OncoSystem Breast is a compilation of Nucletron products and...

NYU Medical Center begins validation study on early detection breast cancer test.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Power3 Medical Products, Inc. (OTCBB: PWRM) announced institutional review board (IRB) approval from New York University Medical Center to begin the clinical validation studies on the company's NAF Test...

PC cell-derived growth factor inflames breast tumor aggression.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- PC cell-derived growth factor inflames breast tumor aggression. According to recent research published in the journal Carcinogenesis, "metastasis is a multi-step process involved in the progression...

Study links low HDL levels with increased risk of postmenopausal breast cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The 2004 update from the American Heart Association's (AHA) Heart Disease and Stroke Statistics, coupled with a recently published study, documents that more than 50 million American women have...

Biomedical foods company receives large order for Asorbine Flex+.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- NutraCea (BULLETIN BOARD: NTRZ) announced that they have received the largest purchase order this year for $240,000 and the second in 2 months from W.F. Young Co. for their Absorbine Flex+ formulation,...

Biotechnology company delists from TSX Venture Exchange.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Oragenics, Inc., (AMEX:ONI) (TSX VENTURE:ORA.U) announced that the company will delist from the TSX Venture Exchange and trade exclusively on the American Stock Exchange (AMEX) under the symbol "ONI."...

Biotechnology company files registration statement with SEC.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Integrated Pharmaceuticals, Inc, has filed a Form 10SB registration statement with the U.S. Securities Exchange Commission (SEC). The statement is now available on the SEC's EDGAR web site; it has...

Pharmaceutical company files universal shelf registration statement.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Nastech Pharmaceutical Company Inc. (Nastech) (NASDAQ:NSTK) announced that it has filed a universal shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC),...

Agilent Technologies to partner in bioinformatics work on $11.7M ATP grant.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Icoria, Inc., (ICOR) announced that Agilent Technologies has been approved by the U.S. National Institute of Standards and Technology (NIST) Advanced Technology Program (ATP) to partner with Icoria in...

Amgen awards 3-year outsourced clinical study support project.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- IT&E International Group (ITER) announced the award of a 3-year, fully outsourced clinical study support project from Amgen, Inc. (AMGN). IT&E was chosen by Amgen to support statistical and clinical...

Biotech company undertakes value-enhancement plan.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Andromed, Inc., (AD) reported a value enhancement and restructuring plan aimed at rapidly raising Andromed's technological and strategic value with a view to a transaction leading to the merger or the...

Biotech firm strengthens drug pipeline by acquiring a phase II compound.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Biofrontera AG announced that it has acquired from ASAT AG, Zug, Switzerland, all intellectual property, know-how and material related to a phase II compound for the treatment of various cancerous...

Cardiology instrument designer and manufacturer added to Russell Indices.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Stereotaxis, Inc. (STXS) announced that it has been added to the Russell 3000 and Russell 2000 Indices, as of October 1, 2004. "As a company that has recently completed an initial public offering,...

Clinical development organization forms centralized document and data centers.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- PRA International (PRA) announced the formation of centralized Document and Data Management Centers. The centers will serve as a single repository for all documents generated during PRA's clinical...

Company changes name and prepares for HIV vaccine trial.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Research company Merix Bioscience announced the change of its name to Argos Therapeutics, Inc. Additionally, the company stated that it is preparing for an HIV clinical trial with Argos' proprietary...

Contract research organization opens office in top German biotech region.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- INC Research has opened an office in Germany, in Dusseldorf's Life Science Center. INC Research strategically located its facility in the North Rhine-Westphalia region of Germany, to be in close...

DNAPrint genomics to acquire majority ownership in German pharmaceutical company.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- DNAPrint genomics, Inc., (DNAP) has agreed to acquire a 51.77% stake in German pharmaceutical company Biofrontera, AG. DNAPrint simultaneously announced that it has received a commitment from...

Drug-testing company expands operations with move to new facilities.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Cozart, plc, announced their move to new premises on the Milton Park estate in Abingdon, Oxford, U.K. Cozart is a medical-diagnostics company which provides immunodiagnostic tests, particularly...

Information solutions company signs multiyear agreement with Boots the Chemist.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- IMS Health (RX) announced a multiyear agreement with Boots The Chemist to deliver more comprehensive, over-the-counter (OTC) healthcare intelligence on the U.K. marketplace. Under the agreement,...

Orthopedic products company presented technology overview at conference.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- ReGen Biologics, Inc., (OTC:RGBI) announced that Gerald E. Bisbee, Jr., PhD, chairman and chief executive officer of ReGen Biologics, will presented an overview of the company's technology and business...

Pharma company and IVAX conclude license agreement for anticancer agent.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Nippon Shinyaku Co., Ltd., and IVAX Corporation concluded a license agreement for a novel anticancer agent, HMN-214. Under the agreement, Nippon Shinyaku has granted IVAX an exclusive license in...

Pharma company announced grant to Health Partners International of Canada.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Paladin Labs Inc. (TSX: PLB) announced that it has donated more than $400,000 in medication to Health Partners International of Canada (HPIC). This is vital support for HPIC's mission of improving...

Pharma marketing organization expands operations.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- PROMOTECH, the specialized marketing support group of Ventiv Health, Inc., (NASDAQ:VTIV) announced the completion of its expansion of operations. This expansion involved adding over 15,000 square...

Pharmaceutical company announces plan to sell Clontech.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Becton, Dickinson and Company (BD, BDX) announced that its board of directors had approved a plan to sell the company's Clontech operation, a unit of BD Biosciences. "The plan to sell Clontech is a...

Report finds integrated operations important priority for pharma industry.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Product Lifecycle Management, a holistic approach that addresses integrated operations such as marketing and sales, is one of the most important priorities for the pharmaceutical industry today,...

Update provided on Latin American operations for diabetes drug.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Robert Rieveley, president of Biotech Holdings (BIO.V; BIOHF), speaking at the company's annual general meeting, provided an update on the company's activities in the Latin American region. "I am...

Biopharma company announces update on trial of compound for advanced cancers.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- NeoPharm (Nasdaq:NEOL) announced that results from a phase I clinical trial of the company's NeoLipid compound LE-SN38 in patients with advanced cancers were presented at the 16th Symposium on Molecular...

New therapy may counteract Paclitaxel resistance in cancer cells.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- As part of the 16th International Meeting of EORTC-NCI-AACR, Indena presented a new line of research based on IDN 5390, a taxane derivative showing a good preclinical profile to counteract Paclitaxel...

Pharmaceutical company enters licensing agreement to develop oral cancer drug.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- IVAX Corporation (IVX) has entered into a licensing agreement with Nippon Shinyaku to develop and market HMN-214, a polo-like kinase inhibitor that targets pancreatic, prostate, and a number of other...

Pharma company presented six studies at cancer therapy conference.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- PharmaMar presented data from six studies, four of which were from pharmacogenomics research projects at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held in...

Data analysis confirms BrachySilTM is safe and effective at tumor regression.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Global nanotechnology company pSivida Limited (ASX: PSD) and Singapore General Hospital (SGH) are pleased to announce Interim data analysis from pSivida's phase IIA trial at SGH has confirmed...

Pharmaceutical company offers phase I trial update for DAVANAT.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Pro-Pharmaceuticals, Inc., (Amex:PRW) announced that a number of patients in its phase I clinical trial are receiving additional cycles (3, 4, & 5) of DAVANAT-1. DAVANAT-1 is a combination of DAVANAT...

Protein biomarkers and drug design for cancer treatments reviewed.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Researchers review protein biomarkers and drug design for cancer treatments in a recent issue of the European Journal of Cancer Prevention. "The development of new cancer treatments is quickly...

Tumor regression reported with AP23573 in relapsed, refractory cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Ariad Pharmaceuticals, Inc., (ARIA) announced, for the first time, updated results of two phase I clinical trials of its novel mTOR inhibitor, AP23573 as a single agent, showing documented tumor...

Scientists develop new drugs that improve survival after bone marrow transplant.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Parker Hughes scientists have developed a new technology capable of improving survival outcomes after bone marrow transplantation. The study was published in the prestigious medical journal, British...

Endogenous Ang II may modulate inward calcium current in the failing heart.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Intracellular and extracellular angiotensin II enhance the L-type calcium current in the failing heart. Scientists in the United States report, "The influence of intracellular and extracellular...

European pharmaceutical awards $1.3M for electrocardiographic services.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- eResearchTechnology, Inc., (eRT) (ERES), provider of centralized electrocardiographic (ECG) collection and interpretation services, has been awarded a thorough phase I ECG (electrocardiogram) study...

Biopharmaceutical company announces CARE 2 study.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Nabi Biopharmaceuticals (NASDAQ:NABI) announced that it is replacing the PhosLo PRECISE Study with the CARE 2 study that will compare efficacy and arterial calcification in patients treated with PhosLo...

Biosciences company enters collaboration to study genetics of heart disease.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- ParAllele BioScience announced that it has entered into collaboration with Novartis Pharma AG to discover genetic variations associated with coronary artery disease. Coronary artery disease affects...

Data on Thelin presented at American College of Rheumatology Meeting.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Encysive Pharmaceuticals (NASDAQ:ENCY) announced that new clinical data on Thelin (sitaxsentan) was presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Antonio,...

New drug designed to reduce cholesterol levels launched.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Lek, a new Sandoz company, launched atorvastatin, a drug designed to reduce cholesterol levels, on the Czech market. Atorvastatin was registered in the Czech Republic on the basis of in-house...

Trial results on COLD-fx show natural compound cuts recurrent colds in half.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- CV Technologies Inc. (CVT) reported on clinical trial results of a year-long pivotal study of COLD-fX conducted by a senior Canadian Researcher and Edmonton's Medical Officer of Health, which showed...

Clinical investigators review, endorse phase 2 trials for deep vein therapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Agenix Limited [AGXLY] announced that clinical investigators to be involved in its phase 2 ThromboView deep vein thrombosis (DVT) clinical trial have met, reviewed and endorsed all aspects of the trial....

Company expands consulting services to full service clinical trials.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Developers of safe and effective pharmaceuticals, biologics, medical devices, and biotechnology products are in a highly competitive environment. Integrated, cost-conscious planning and execution of...

Strategic alliance to provide turnkey solution for clinical trials.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- InforMedix Holdings, Inc., (IFMX) announced a strategic alliance with McKesson BioServices, a subsidiary of McKesson Corporation (MCK), to jointly provide a turnkey patient-compliance and...

Agreement inked to produce first-ever products from chloroplasts.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Chlorogen, Inc., has signed a joint development and supply agreement with Sigma-Aldrich Fine Chemicals, a division of Sigma-Aldrich Corp. (SIAL), which is expected to produce the first commercial...

Agreement signed to market docosanol 10% cream in Scandanavia.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Avanir Pharmaceuticals (AVN) announced that it has signed an exclusive agreement with ACO HUD to manufacture and market Avanir's docosanol 10% cream as a treatment for cold sores in Sweden, Norway,...

Agreement signed with Tegent Technology to establish distribution in China.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Tegent Technology, Ltd., (Tegent) and Advanced Chemistry Development, Inc., (ACD/Labs) announced their agreement, which establishes Tegent as the master distributor of ACD/Labs software in China,...

Alliance to develop novel anticancer compound.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- ImmunoGen, Inc., (IMGN) and Biogen Idec, Inc., (BIIB) announced that Biogen Idec has licensed exclusive rights to use ImmunoGen's proprietary Tumor-Activated Prodrug (TAP) technology with antibodies to...

Altana Pharma selects partner for a kinase lead identification program.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Evotec OAI AG (EVT, TecDAX 30) announced that it has signed an agreement with Altana Pharma AG to advance the discovery on one of their kinase targets. Applying Evotec OAI's drug discovery engine...

Antibody alliance with Centocor expanded.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Biolex, Inc., a privately held protein therapeutics company, announced an expanded collaboration with Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson, to include two additional proteins....

Biogen enters pharmacodiagnostic research collaboration.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Epigenomics, AG, (ECX), a molecular diagnostic company developing tests based on DNA methylation, announced that the company has entered into a research collaboration with Biogen Idec (BIIB) to identify...

Chemical compound catalogs added to cheminformatics database.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Accelrys, Inc., (ACCL) announced an agreement to integrate the Sigma-Aldrich (SIAL) chemical compound catalogs into Accelrys' chemical suppliers database, Chemicals Available for Purchase (CAP). ...

Cooperation, license agreements signed related to mouse genetics.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Artemis Pharmaceuticals GmbH (Cologne) and Boehringer Ingelheim (Ingelheim, Germany and Ridgefield, Connecticut) have signed service and license agreements in the area of mouse genetics and genomics....

Device companies announce distribution agreement for nebulizer system.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Aerogen, Inc., (AEGN) and Respironics, Inc., (RESP) announced that they have entered into a worldwide, non-exclusive distribution agreement for Aerogen's Aeroneb Professional Nebulizer System (Aeroneb...